Related Experiment Video
Updated: Jun 22, 2025

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Leveraging Integrated RNA Sequencing to Decipher Adrenomedullin's Protective Mechanisms in Experimental
Subarna Palit1, Amrit Kumar Shrestha2, Shyam Thapa2
1TUM School of Life Sciences Weihenstephan, Technical University of Munich, 85354 Freising, Germany.
Insights
Adrenomedullin (Adm) protects against experimental bronchopulmonary dysplasia (BPD) by reducing inflammation and altering immune cell populations. This suggests Adm is a potential therapeutic target for infants with BPD.
Area of Science:
- Pulmonary Medicine
- Molecular Biology
- Immunology
Background:
- Bronchopulmonary dysplasia (BPD) is a chronic lung disease in premature infants with few treatments.
- Adrenomedullin (Adm), a peptide hormone, shows protective effects in experimental BPD models.
Purpose of the Study:
- To investigate the molecular and cellular mechanisms of Adrenomedullin (Adm) in bronchopulmonary dysplasia (BPD) pathogenesis.
- To utilize a lipopolysaccharide (LPS)-induced mouse model for studying experimental BPD.
Main Methods:
- Bulk and single-cell RNA sequencing of wild-type and Adm-haplodeficient mouse lungs exposed to LPS.
- Computational integration with cell atlas data and analysis of human BPD patient data.
Main Results:
- Adm deficiency and LPS exposure altered lung gene expression and cell types.
- Adm-haplodeficient lungs showed increased inflammation, higher natural killer (NK) cell frequency, and reduced endothelial and type II pneumocyte cells.
- Human BPD infant data confirmed elevated NK cell frequencies.
Conclusions:
- Adrenomedullin plays a protective role in experimental BPD.
- Adm influences BPD pathogenesis by modulating immune cell populations and lung cell frequencies.
- Adm represents a potential therapeutic target for BPD, particularly in cases with an inflammatory phenotype.
Abstract:
Bronchopulmonary dysplasia (BPD) is a chronic lung disease commonly affecting premature infants, with limited therapeutic options and increased long-term consequences. Adrenomedullin (Adm), a proangiogenic peptide hormone, has been found to protect rodents against experimental BPD. This study aims to elucidate the molecular and cellular mechanisms through which Adm influences BPD pathogenesis using a lipopolysaccharide (LPS)-induced model of experimental BPD in mice. Bulk RNA sequencing of Adm-sufficient (wild-type or Adm+/+) and Adm-haplodeficient (Adm+/-) mice lungs, integrated with single-cell RNA sequencing data, revealed distinct gene expression patterns and cell type alterations associated with Adm deficiency and LPS exposure. Notably, computational integration with cell atlas data revealed that Adm-haplodeficient mouse lungs exhibited gene expression signatures characteristic of increased inflammation, natural killer (NK) cell frequency, and decreased endothelial cell and type II pneumocyte frequency. Furthermore, in silico human BPD patient data analysis supported our cell type frequency finding, highlighting elevated NK cells in BPD infants. These results underscore the protective role of Adm in experimental BPD and emphasize that it is a potential therapeutic target for BPD infants with an inflammatory phenotype.
More Related Videos
04:21A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease
Published on: August 4, 2021
08:44Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
Published on: May 30, 2020